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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not “Is the use
of a PORT as opposed to a PICC more effective in improving quality of life in patients receiving
chemotherapy?”
Study Design: Review of three randomized control trials (RCTs) including one monocentric
RCT, one two-centre RCT, and one multi-centered RCT.
Data Sources: All articles were published in English and taken from peer-reviewed journals
using PubMed. All articles were published between 2014-2020 and chosen based on their
relevance to the clinical question.
Outcome Measured: The outcome measured was quality of life (QoL). The studies used
patient-reported homemade questionnaires and/or a validated QLQ-C30 questionnaire. For
consistency assessments provided at a 6-month interval from insertion were utilized.
Results: In the RCT led by Taxbro, et al.1 indicated no significant difference in QoL overall, but
a significant difference in QoL for certain activities encompassing global health. A significant
difference was noted in taking a bath (p=0.004) and working out (p=0.052). No significant
difference was noted with discomfort (p=0.616), showering (p=0.382), arm movement
(p=1.000), or getting dressed (p=1.000). Patel, et al.4 examined patient-rated questionnaires that
were used to generally assess QoL. Although specific data was not provided, results stated: “no
significant differences were noted between the groups in the quality-of-life measures examined.”
Patel et al. did note a significant difference in median dwell time for PORTs compared to PICCs
(p=0.0057) which may have impacted results if it were included in the questionnaire.4 In the
RCT performed by Clatot, et al., the validated questionnaire used indicated patients with PORTs
did not indicate improved QoL compared to patients receiving PICCs (p=0.48). The mean
difference between PICCs and PORTs was 3.4 (p=0.48).8 The study also contained a homemade
questionnaire assessing global satisfaction as QoL. Results were reported as mean scores.
Comparison of the PICC and PORT groups indicated no significant differences (p=0.78).
Conclusion: One of the studies demonstrated that patients with PICCs reported a significantly
worse QoL. Two studies indicated QoL did not differ significantly between patients receiving
chemotherapy via a PICC or a PORT.
Key Words: peripherally inserted central catheter, implanted port catheter, quality of life
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INTRODUCTION
Chemotherapy is used to treat a wide range of cancers in both adults and children. While
best practices for use and duration have been established according to cancer types, optimal
practices for vascular access remain under debate.1 Between 2018 and 2040, an estimated
number of patients requiring first-line chemotherapy globally each year will increase 53% from
9.8 million to 15 million if all patients are treated according to evidence-based guidelines.2
Consequently, understanding the safety and reliability of a venous access device is becoming
increasingly important for both medical providers and patients.
With the expansion of cancer treatments in the United States, the economic burden of
cancer has increased significantly.3 The estimated prevalence cost of cancer in 2010 was $124.5
billion, and if incidence, survival, and costs of care remained at constant levels, the cost was
projected to increase to 157.8 billion by the year 2020.3 Estimates and projections are comprised
of direct medical costs and indirect costs. It is difficult to determine an exact amount for each
component, however, it is known treatments including chemotherapy are a substantial factor
within direct medical costs.3 Safe and reliable venous access devices (VADs) not only play an
important role in controlling costs but also contribute to quality patient care.3
The use of central venous catheters (CVCs) has become a critical component of patient
care during chemotherapy treatment. Catheters are used to provide prolonged access to the
bloodstream for the effective delivery of chemotherapy and blood products.4 Some benefits of
using CVCs for chemotherapy treatment included reduced needle sticks, avoidance of bruising or
bleeding, and administering more than one medication at a time.5 The United States purchases
approximately 150 million intravenous catheters per year.5 Two types of widely used catheters
are peripherally inserted central catheters (PICCs) and implanted central venous catheters
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(PORTs). A PICC is commonly inserted in the basilic, brachial, or cephalic vein.5 PICCs are
more easily inserted than PORTs and are often used in patients requiring up to six months of
intravenous chemotherapy. They require frequent flushing and dressing changes.5 PORTs are
surgically implanted in the chest wall or upper arm and require less frequent flushing but are
more difficult and time-consuming to insert and remove.6 PICCs and PORTs may influence
quality of life (QoL) differently due to factors such as visibility, pain, clothing restrictions, and
interference with activities of daily living; however, scientific evidence outlining patient
satisfaction is limited. This paper evaluates three randomized controlled trials examining the
effects of a PORT as opposed to a PICC venous access device on QoL in patients receiving
chemotherapy.
OBJECTIVE
The objective of this systematic review is to determine whether “Is the use of a PORT as
opposed to a PICC more effective in improving quality of life in patients receiving
chemotherapy?”
METHODS
The population targeted for this review included male and female patients > 18 years of
age diagnosed with cancer and requiring chemotherapy. The intervention being examined for
venous access is a PORT, the comparator is a PICC. The outcome being measured is improved
quality of life. The types of studies included in this evidence-based medicine (EBM) review are
an open-labeled, two-centre RCT, a multi-centered RCT, and a mono-centric, phase II RCT.
All articles were published in English in peer-reviewed journals between 2014-2020. The
articles were obtained from PubMed and selected based on relevance to clinical questions as well
as the content of patient-oriented evidence that matters (POEMS). Keywords used to acquire the

Coia | Venous Access & Quality of Life
articles included “peripherally inserted central catheter”, “implanted central venous catheter”,
“quality of life”, and “chemotherapy”. Inclusion criteria were articles published within the last
10 years, adults > 18 years old, and randomized controlled trials. Exclusion criteria included
studies >10 years old, pediatric patients, non-cancer patients, and systematic reviews. A
summary of statistics reported includes p-values, NNTs, mean scores and subjective rating
scales. Table 1 denotes the demographics and characteristics of the included studies.
Table 1 – Demographics and Characteristics of Included Studies
Study
Type
#
Age
Inclusion
Exclusion
W/D
Pts (yrs)
Criteria
Criteria
Taxbro Open- 399 >18 Life expectancy
Ongoing severe
15
1
(2019) Labeled
yrs
longer than 4
systemic infection,
Twoweeks, requiring clinically significant
centre
chemotherapy
upper extremity/
RCT
through venous
central DVT,
access
inability to
communicate, severe
coagulopathy, or an
imminent need for
dialysis fistula
Patel
Multi70
>18
Adult patients
Patients with
2
(2014)4 centred
yrs
with nonhaematological
RCT
hematological
cancer, children and
malignancy,
adolescent patients
chemotherapy
through venous
access, projected
life expectancy >
3 months
Clatot
Mono- 253 >18
Females,
Males, Metastatic
3
(2020)7 centric
histologically
breast cancer, altered
phase II
confirmed EBC
haemostasis,
RCT
treated with
inflammatory breast
curative intent
cancer, cutaneous
and an indication disease, thrombosis
of anthracycline of upper body in last
+ taxane-based 12 months, inclusion
ACT
in trial, tracheotomy

Interventions
PICC vs
PORT

PICC vs
PORT

PICC vs
PORT

3
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OUTCOMES MEASURED
The outcome measured in this EBM review included improved QoL for patients
receiving chemotherapy through a PICC or PORT device. To more globally assess QoL, multiple
outcomes were combined in all three studies. In the study conducted by Taxbro et al.,1 QoL was
measured using a numeric rating scale (NRS) completed by patients regarding interference with
daily activities and discomfort. A generalized discomfort score was calculated by totaling
individual component scores and p-values were obtained by use of the Chi2 or Fishers test.1 In the
study by Patel et al.,4 patients were asked to rate QoL by lifestyle factors in the following
manner: not at all, a little, or quite a bit using a non-validated, study-specific central venous line
questionnaire. Data was collected every three weeks during the study until catheter removal or
six months, whichever was sooner.4 In the study by Clatot et al.,7 the European Organisation for
Research and Treatment of Cancer QLQ-C30 score along with a home-made device satisfaction
questionnaire dedicated to venous devices were used to analyze QoL.7 The QLQ-C30 included
functional and symptoms scales to globally assess health status. The analysis was given postimplantation, mid-treatment, and end of treatment. The satisfaction questionnaire forms
comprised of designated questions to evaluate four scales: anxiety/pain, discomfort, satisfaction,
and global acceptance. Questionnaires were self-administered four times throughout the study:
the day of the first chemotherapy administration (after implantation), mid-treatment, three weeks
after last administration (end of treatment), and 35 weeks after implantation (end of follow-up).7
The overall rating used a 4-point scale, 1 indicating not at all and 4 indicating a lot.7
RESULTS
Taxbro et al. conducted an open-labeled, two-centre RCT that compared two types of
central venous catheters (PICC and PORT) in patients with non-haematological cancer. A total
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of 399 participants >18 years old, with life expectancy longer than 4 weeks, and requiring
chemotherapy through a central venous device were selected for this study between March 2013
and February 2017.1 Individuals were chosen based on specific inclusion and exclusion criteria
detailed in Table 1. Patients were randomized in a 1:1 allocation ratio to either a PICC or a
PORT at two county oncology centers in Sweden. In total, 201 patients received a PICC while
198 patients received a PORT.1 The randomization sequence was computer-generated and
prepared by an independent statistician using a block size of four and stratification to the two
centers.1 Due to the properties of the catheters, it was not feasible to “blind” the patient, clinician,
or trial assessors. Statistical data used to measure generalized discomfort in this study, presented
as p-values, was collected from both groups after catheter implantation and at follow-up intervals
of 1, 3, 6, and 12 months. To keep consistency between study results, this review will focus on a
six-month follow-up interval.
For this EMB review, patient-reported multiple outcomes were combined to more
globally assess QoL. Results were 54.2% in the PICC group and 28.2% in the PORT group
(Table 2).1 The PICC group results showed statistical significance in interference with some
daily activities including bathing (p= 0.004) and working out (p= 0.052). No significant
difference was reported with arm movement, showering, and getting dressed.1 The study also
reported a p-value of 0.616 for discomfort indicating no statistical significance amongst the
groups. The calculated NNT, -3, demonstrated a small treatment effect and implies no clinical
significance (Table 3).1
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Table 2. Comparison of Discomfort and Interference of the Study Groups Month 6 After
Insertion (data from Taxbro et al.)1
Patient Reported (%)
p-value
PICC
PORT
Discomfort
5/39 (12.8) 19/105 (18.1)
0.616
Interference: Showering
3/40 (7.5)
4/107 (3.6)
0.382
Taking a bath
4/17 (23.5)
2/98 (2)
0.004
Working out
3/38 (7.9)
1/110 (0.9)
0.052
Moving Arm
1/40 (2.5)
2/110 (1.8)
1.000
Getting Dressed
0/40 (0)
2/110 (1.8)
1.000
Table 3. Calculations for Treatment from Taxbro et al.1
Study
CER
EER
RBI
Taxbro et al.
0.54
0.28
0.48

ABI
0.38

NNT
-3

Patel et al. conducted a multi-centered RCT similar in design to Taxbro et al. examining
the self-reported quality of life variables between PICCs and PORTS in the delivery of
chemotherapy in patients with non-haematological cancer. Seventy patients from three
Australian centers: Flinders Medical Centre (n=45), The Queen Elizabeth Hospital (n=2), and
Monash Cancer Centre (n=23) were randomized 1:1 to receive a PICC or a PORT device.
Eighty-one patients were deemed eligible between December 2004 and January 2010, however,
11 declined participation due to a preference of CVC type. The 70 remaining patients (29-84
years of age) with a projected life expectancy of at least 3 months and requiring chemotherapy
through a central venous device were randomized, but 2 withdrew prior to device insertion.4
Inclusion and exclusion criteria are noted in Table 1.
All three facilities in this study specified the PICC line tip was placed at the caval-atrial
junction, and the position was checked radiologically at the end of the procedure.4 PORT
insertion was performed by a surgeon on all patients. Catheter care for both types of devices was
performed by a specialist trained catheter care nursing team in the hospitals.4 Notably, the
median dwell time was longer for PORTs compared to PICCs.4 The calculated p-values for
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median dwell time was 0.0057 indicating a statistical significance in both amongst patients in
this study. See values presented in Table 4 below.
Quality of life data was obtained from 36 patients (53%) using a non-validated studyspecific questionnaire covering functional status, sleep, and hygiene disturbance. Data was
collected in three-week intervals until catheter removal with a maximum of six months.4
Numerical figures on quality of life were not provided by researchers; therefore, a NNT could
not be calculated. Subjective measures summarizing patient questionnaire responses indicated
the PICC group reported “not at all” to “a little” interference with lifestyle factors in five of the
seven areas examined: clothing, help required. for CVC problems, sleep, activities of daily living,
and social life. “A little” to “quite a bit” interference was noted in personal hygiene and work
activities.4 The PORT intervention group demonstrated no area rated greater than “a little”
interference with all seven lifestyle factors.4 There was no reported p-value, however, the author
did report that “No significant differences were noted between the groups in the quality-of-life
measures examined.”4
Table 4. Comparison of Dwell Time Between Groups (data from Patel et al.4)
PICC Group
PORT Group
p-value
Median dwell time (days)
115
160
P=0.0057
The final study conducted by Clatot et al.7 was a monocentric, phase II, RCT evaluating
QoL variables between PICCs and PORTS in the delivery of adjuvant chemotherapy (ACT) in
patients with early breast cancer (EBC). Between February 2014 and May 2018, 751 patients
from the Henri Becquerel Cancer Centre in France were screened for the study. From that
population, 189 patients were deemed ineligible and 306 refused to participate. The remaining
256 patients were randomized by a computer at a 1:1 allocation ratio to receive a PICC (n=128)
or a PORT (n=128) device.7 Three patients withdrew consent after randomization and were
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excluded from the final analysis. Inclusion and exclusion criteria for the participating 253
patients (30-74 years of age) are noted in Table 1.
PICC devices were implanted using the basilic or brachial vein and PORTs were
implanted using the jugular or subclavian vein. PICCs were removed on the day of the last
chemotherapy administration. PORTs were removed 4 weeks after the last chemotherapy
administration. Patients in this study by Clatot et al.7 provided ratings on the day of the first
chemotherapy administration (post-implantation), at mid-course of chemotherapy treatment
(mid-treatment), at 3 weeks after last chemotherapy administration (end of treatment), and at 35
weeks after implantation (end of follow-up). Due to the low response rate, only the results of the
first 3 times were detailed using the EORTC QLQ-C30 analysis.7 For consistency with time
comparisons among the studies, this review will focus on end of treatment data.
The statistical data used by Clatot et al. to measure QoL by each group was presented as
mean values, standard deviation, and p-values.7 Data was obtained from a validated
questionnaire, The European Organization for Research and Treatment of Cancer’s cancerspecific quality of life questionnaire (EORTC QLQ-C30). The questionnaire consists of
functional and symptom scales in addition to a global health status/quality of life (GHS/QoL).
Due to clinical relevance to this review’s question, only the GHS/QoL data is being utilized. The
PICC comparator group showed a mean score of 64.4 with a standard deviation of 18.9 at postimplantation.7 The p-value for scores was 0.48, demonstrating no significant difference in QoL
as shown in Table 5.7
Table 5. EORTC QLQ-C30 Global Health Status Analysis Between PICC and PORT
Groups (data from Clatot et al.7)
Mean Difference Between
Mean + SD
Groups (calculated)
P-Value
64.4 + 18.9
PICC Group
3.4
0.48
PORT Group (Intervention)
61 + 21.4
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The second type of data used by Clatot et al. to measure QoL was a self-administered,
homemade patient questionnaire.7 Results were presented as mean values and p-values. The
PICC group showed a mean global score of 93.3 end treatment.7 The PORT intervention group
demonstrated a mean global score of 93.5 end treatment.7 The p-value for global scores was
p=0.78 end treatment indicating the results were not statistically significant within the
population.7 The values for this study can be seen in Table 6 below.
TABLE 6. Catheter-Related Global Satisfaction End Treatment (data from Clatot et al.7)
Mean
P-Value
PICC Group
93.3
P=0.78
PORT Group Intervention
93.5
DISCUSSION
Over the last decade, new chemotherapy combinations and more complex treatment
regimens have been developed to care for cancer patients.5 As a result, vascular access devices
are being widely used to facilitate these treatments. Although VADs play an important role in
patient care, there is a lack of conclusive data in the literature supporting the choice of the most
appropriate device, particularly in terms of quality of life. The objective of this systematic review
was to determine if the use of a PORT as opposed to a PICC is more effective in improving QoL
in patients receiving chemotherapy. The three articles reviewed in this EBM demonstrated a
small treatment effect and indicated no significant overall improvement in QoL between patients
receiving a PICC or a PORT. Taxbro et al.1, who had the largest sample population of the three
studies, demonstrated an insignificant overall difference in QoL amongst the groups; however,
PORTS were perceived to have less effect on specific daily activities contributing to the overall
score. Significant differences were reported for taking a bath (p-value = 0.004) and working out
(p-value = 0.052).4
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The study conducted by Patel et al.4 which had the smallest sample population out of the
three studies, demonstrated patients who received a PICC reported a greater impact in hygiene
and work activities than patients with a PORT. Patients with a PORT rated less overall
interference with lifestyle factors. Although statistical data was not provided, the study’s authors
reported no significant differences were noted between the groups.4 Interestingly, Patel et al. did
suggest a need for additional studies to further examine the statistical significance in the median
dwell time between PICCs and PORTs and its possible effect on QoL.4 Clatot et al. performed a
study generalizable to only one center using two types of questionnaires (one validated and one
homemade) to assess global health status as QoL. Results of the validated questionnaire yielded
a mean score difference of 3.4 and a p-value of 0.48 indicating no significant difference in QoL
between PICCs and PORTs.7 The homemade questionnaire yielded a group comparison p-value
of 0.78 also indicating no significant difference between PICC and PORT groups.7
The studies used in this review consisted of several limitations. In all three studies,
participants were unable to be kept “blind” to the intervention.1,4,8 This could present a potential
impact or bias due to patient and physician device preference. The three studies also contained
small sample sizes. Patel et al. related slow patient recruitment and failure to reach target sample
size to patient and physician preference, refusal, and death.4 Taxbro et al. and Clatot et al.
reported a high participant refusal rate of 54% and 51% respectively.4,7 Lastly, all three studies
mentioned the need for a validated or refined questionnaire focusing solely on QoL factors. The
studies performed by Taxbro et al. and Patel et al. used non-validated, homemade questionnaires.
The study by Clatot used one validated and one non-validated questionnaire; however, both
measures indicated no significant difference in QoL.7
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Additional limitations were present within the individual studies. The studies by Taxbro
et al.,1 and Clatot et al.7 noted a difference in “passive” dwell and exposure time for patients with
PORTs, which could influence the interpretation of time-dependent data. Patients in Taxbro et
al.1’s study had a wide range of solid tumor cancers and could be receiving adjuvant or palliative
care. This can limit the ability to interpret results regarding specific diagnoses.1 Patel et al.
indicated possible compromise due to local-regional factors such as availability of skills and
resources.4 Expertise at local hospitals and cancer centers with insertion and management of a
VAD may vary. Patel et al.’s study contained three centers; therefore, a higher level of variability
may have occurred. Clatot et al.7 identified a difference in implantation sites for PICCs and
PORTs as a limitation. Heterogeneity of catheter positioning among patients may have increased
validity in the results of the study.
CONCLUSION
All three randomized controlled trials in this EBM review yielded a lack of evidence to
demonstrate improved quality of life for oncology patients using a PORT compared to a PICC
while receiving chemotherapy. Studies completed by Taxbro et al. and Clatot et al. found a small
treatment effect as p-values and NNT did not demonstrate a statistical significance. P-values
were not given in the Patel et al. study; however, the authors noted “no statistical difference
between groups” therefore, it can be extrapolated that the treatment effect was small.
Future studies evaluating and comparing this aspect of care are needed to assess quality
of life more adequately. Additional trials are needed with a larger sample size given the indicated
refusal rate of participants. Additionally, considering differences in cultural and regional factors
including availability of skills and resources for inserting and managing central venous catheters
and median exposure time between devices would be of greater benefit.4 Questionnaire
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refinement and validation in further studies are also essential as patient comments identified
interferences with QoL that were not included on the questionnaire but were important to patient
lifestyle.4 At the time of my research, additional information on current ongoing studies was not
found; however, these devices continue to be used regularly to gain venous access.6 Reliable
data on this essential aspect of care is vital in the quest to provide improved QoL for the millions
of patients receiving chemotherapy treatments each year.
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